
解读VERTIS‐CV试验的结果:这是“类效应”视角的终结吗?
Author(s) -
Koufakis Theocharis,
Papanas Nikolaos,
Dimitriadis George,
Zebekakis Pantelis,
Kotsa Kalliopi
Publication year - 2020
Publication title -
journal of diabetes
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.13105
Subject(s) - medicine , canagliflozin , myocardial infarction , clinical endpoint , placebo , diabetes mellitus , type 2 diabetes , stroke (engine) , heart failure , mace , dapagliflozin , adverse effect , randomized controlled trial , cardiology , endocrinology , percutaneous coronary intervention , pathology , mechanical engineering , alternative medicine , engineering